Fundraising Fox

Lyn Baranowski

CEO at Avalyn Pharma Inc

Boston, Massachusetts, United States

Find your path to Lyn

423 people in our graph share verified history with Lyn — schools, employers, funds. One of them is your warm intro.

Micah RosenbloomunlockedLyn: together at Harvard Business School (2001–2003)
×7Lyn: together at Harvard Business School
×4Lyn: together at American University

About

Lyn Baranowski is the Chief Executive Officer of Avalyn Pharma Inc. (NASDAQ: AVLN), a clinical-stage biopharmaceutical company developing inhaled therapies for rare lung diseases, including pulmonary fibrosis and other interstitial lung diseases. She has over 20 years of biopharma experience, has raised more than $620 million for Avalyn including its 2026 IPO, and previously contributed to the development and commercialization of therapies such as BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA. Baranowski holds an MBA from Harvard Business School, serves on the Board of Advisors for Life Science Cares, and was a 2024 PharmaVoice 100 award recipient.

CEO at Avalyn Pharma Inc

Intro paths

→

In turn, Lyn can intro founders to Avalyn Pharma Inc's investors below.

Avalyn Pharma Inc's investors · 15

Andera PartnersParisCatalio Capital ManagementNew York · since 2023Catalio Capital Management, LPNew YorkF-Prime CapitalCambridge · $3M – $10M checks · since 2023InVivium CapitalChicagoNorwest Venture PartnersMenlo Park · $10M – $30M checks · since 2023Novo HoldingsCopenhagen · $1.1M – $54M checks · since 2026Perceptive Xontogeny VentureNew YorkPivotal Life SciencesSan Francisco · since 2023RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2023Rock Springs CapitalBaltimore · since 2023SR One Capital ManagementRedwood CityT. Rowe PriceBaltimore · since 2023Vida VenturesLos Angeles · since 2023Wellington ManagementBoston · $5M – $50M checks · since 2023

Experience

  1. Avalyn Pharma Inc.Chief Executive Officercurrent2022 — present
  2. Rani TherapeuticsMember of the Board of Directors2021 — 2023
  3. Altavant SciencesChief Operating Officer2018 — 2022New York, New York
  4. Melinta TherapeuticsSenior Vice President, Corporate Development & Strategy2013 — 2018New York City Metropolitan Area
  5. Pearl TherapeuticsVice President, Commercial Development2011 — 2013New York City Metropolitan Area
  6. Vatera HealthcareVice President2008 — 2013
  7. Novartis PharmaceuticalsDirector2005 — 2008
  8. Novartis PharmaceuticalsSenior Policy Advisor2003 — 2005
  9. Dewey Ballantine LLPInternational Trade Analyst1999 — 2001
  10. U.S. Department of Commerce, ITA, Import Admin.International Trade Analyst1997 — 1999

Skills & more

Strategy46Negotiation1Organizational LeadershipVenture FinancingDeal ExecutionBiopharmaceuticals4Private Equity7Biotechnology15Dermatology12Venture Capital40Lifesciences5Technology Transfer4
+10 moreMergersClinical DevelopmentOncologyBusiness StrategyRegulatory AffairsHealthcareMergers & AcquisitionsMedical DevicesProduct LaunchDrug Development

From Lyn's professional profile.

Frequently asked questions

Who is Lyn Baranowski?
Lyn Baranowski is the Chief Executive Officer of Avalyn Pharma Inc. (NASDAQ: AVLN), a clinical-stage biopharmaceutical company developing inhaled therapies for rare lung diseases, including pulmonary fibrosis and other interstitial lung diseases. She has over 20 years of biopharma experience, has raised more than $620 million for Avalyn including its 2026 IPO, and previously contributed to the development and commercialization of therapies such as BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA. Baranowski holds an MBA from Harvard Business School, serves on the Board of Advisors for Life Science Cares, and was a 2024 PharmaVoice 100 award recipient.
Where does Lyn Baranowski work?
Lyn Baranowski is CEO at Avalyn Pharma Inc.
Where did Lyn Baranowski go to school?
Lyn Baranowski studied at Harvard Business School (MBA, General Management); Stanford University Law School: Directors College (Directors' College, Public company Board of Directors executive education training); American University (B.A., International Studies).

Same school

Also attended Harvard Business School2,000

Brad GerstnerFounder & CEO of Altimeter CapitalVictoria TreygerGeneral Partner at Felicis VenturesDeep NisharInvestment Team at General CatalystJohn KimInvestor Relations at General CatalystAdrianna MaInvestor at Index VenturesNeil RimerInvestor at Index Ventures

+ 1,994 more

Also attended American University161

Vincent DialloInvestor at DaphniAmanda ThickpennyEvents Manager at NorthzoneSidd SrinivasaVenture Partner at Madrona Venture GroupBaxter BlackSenior Applied Data Scientist at Madrona Venture GroupCarleigh MorbaInvestor at Index VenturesMark KraynakInvestor at Aspect Ventures

+ 155 more

Shared employers

Also worked at Avalyn Pharma Inc.4

Jonathan LeffExecutive Partner, Private Equity at Sofinnova VenturesShawna FrazierDirector at AbbVieTrey JenningsAssociate at Norwest Venture PartnersErin LavelleExecutive Officer at Eliem Therapeutics

Also worked at Rani Therapeutics2

Talat ImranExecutive Officer, Director at Rani Therapeutics HoldingsSvai SanfordExecutive Officer at Rani Therapeutics Holdings

Also worked at Melinta Therapeutics3

Eddie YangAnalyst at Deerfield Management CompanyDan WechslerCEO / Managing Partner at Blue Star Innovation PartnersLisa DeFrancescoExecutive Officer at Lexicon Pharmaceuticals

Also worked at Novartis Pharmaceuticals246

Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures

+ 240 more